Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

@inproceedings{Combe2014EfficacyAS,
  title={Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study},
  author={Bernard G Combe and Bhaskar Dasgupta and Ingrid Louw and Sarvajeet Pal and Juergen Wollenhaupt and Cristiano Augusto de Freitas Zerbini and Andr{\'e} D. Beaulieu and Hendrik Schulze-Koops and Patrick Durez and Ruji Yao and Nathan Vastesaeger and Haoling H. Weng},
  booktitle={Annals of the rheumatic diseases},
  year={2014}
}
OBJECTIVES To evaluate the efficacy and safety of subcutaneous golimumab as add-on therapy in patients with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD) treatment. To evaluate an intravenous plus subcutaneous (IV+SC) golimumab strategy in patients who had not attained remission. METHODS GO-MORE was an open-label, multinational, prospective study in patients with active RA in typical clinical practice settings. In part 1, patients received add-on… CONTINUE READING